{"id":949716,"date":"2026-04-08T06:03:40","date_gmt":"2026-04-08T10:03:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/"},"modified":"2026-04-08T06:03:40","modified_gmt":"2026-04-08T10:03:40","slug":"ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/","title":{"rendered":"AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts<\/li>\n<li>Durable responses observed at Day 85: 83% (5\/6) (10 mg) and 66.7% (4\/6) (12 mg)<\/li>\n<li>BPL-003 received FDA Breakthrough Therapy Designation in October 2025<\/li>\n<li>Phase 3 initiation on track for Q2 2026\n<\/li>\n<\/ul>\n<p>NEW YORK, April  08, 2026  (GLOBE NEWSWIRE) &#8212; AtaiBeckley Inc. (NASDAQ: ATAI) (\u201cAtaiBeckley\u201d or \u201cCompany\u201d), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced peer-reviewed Phase 2a results (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EOdfoKHLADnsZKkK7TLYCdGlYMfD10uEFzkXe0L09FeaDNbPzk7ZOe9pYBjdNAxJgU0RFy3nw9YPcvHiHvg5mykgrySSg6ffyYxAiZ7J0a3obdChwj4FJa_KVsswjGXh\" rel=\"nofollow\" target=\"_blank\">NCT05660642<\/a>) in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E0hWyd2Q6u4ayrsg3cngG84sPAzpE9wU03zx5dKi11jexsCOP6CCFGzQsQAMAFpFZDwqGyrye34EZ2nwfaXBPBdG5SP-s1901M2jsuHIuBk9KvVgejETRAWQ30Izmgld\" rel=\"nofollow\" target=\"_blank\"><em>CNS Drugs<\/em><\/a> demonstrating that a single intranasal dose of BPL-003 (mebufotenin benzoate), which holds <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hGdOa4vLrBKBf0XMxkKNbD3l_pFddRIXPo-Ddfmu9rjsCCSEZmLT-XvPVGsgGA1Ni862GoYW4W_PZuiRz9CoQ2zPoyv1MLrwsrOSv5DHDhReSADn-dld8m6nzoamn9UT3ikcxFwKPvLV_WYWpSut6Yd_mLQertI558Bsv7leXvBFkf8zUXs3PHOkpN_e4km0G_yC6h45U4T-0-yUNyWg0JrGdK_B8nJzO8o9J5s1MNtHK6twKLUe3fc3NSq3nECd\" rel=\"nofollow\" target=\"_blank\">FDA Breakthrough Therapy Designation<\/a>, achieved rapid and sustained reductions in MADRS scores from baseline in participants with treatment-resistant depression (TRD) who remained on stable SSRI therapy throughout the study (n=12). A 66.7% antidepressant response rate (\u226550% reduction from baseline MADRS score) was observed at Day 2 in both the 10 mg (n=6) and 12 mg (n=6) cohorts, with 83% (5\/6) of participants in the 10 mg cohort and 66.7% (4\/6) of participants in the 12 mg cohort maintaining a response at Week 12. BPL-003 was generally well tolerated with no serious adverse events reported, and participants achieved a mean discharge approximately 100 minutes post-dose. Phase 3 studies are on track to initiate in Q2 2026 following\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cYbl2-jslvmQ3lTqAL4htvF0UAbY59nR-eLO5b-UmO-SiyEx6hkX3_Oc2B76LCF-oFHXir84atXEogXsiY2jhGib0CmSnmJeiYbDRb7fJWcWBwgGrtsW1ExUuFWTf3-8Fha7TropmL1fR2-3_CpHhLfJzKQBMejJmZH7JnPGUsE-dNn8jXQEZQqcbZU3OP-facXXajlDePrgMeH5hjdDbHSPi-zwvOGO8wwRAH1RfrzMO1UaIrCE7kXPif_xZwXA\" rel=\"nofollow\" target=\"_blank\">recent FDA End-of-Phase 2 (EOP2) alignment<\/a>.<\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Clinical Data Summary<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:12%;width:12%;min-width:12%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Drug<\/strong>\n          <\/td>\n<td style=\"max-width:88%;width:88%;min-width:88%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">BPL-003 (mebufotenin benzoate intranasal spray)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Mechanism<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">5-HT1A and 5-HT2A agonist associated with rapid onset and treatment experience of ~2 hours<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Indication<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Treatment-resistant depression (TRD); failure to respond to \u22652 prior antidepressants at adequate dose and duration<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Designations<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">U.S. FDA Breakthrough Therapy Designation granted October 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Trial<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05660642\" rel=\"nofollow\" target=\"_blank\">NCT05660642:<\/a> four-part Phase 2a open-label study. Part 2 (SSRI-concomitant, n=12) reported here; Part 1 (monotherapy, single dose, n=12) published in <a href=\"https:\/\/ir.ataibeckley.com\/news-releases\/news-release-details\/bpl-003-demonstrates-rapid-and-durable-antidepressant-effects\" rel=\"nofollow\" target=\"_blank\">Journal of Psychopharmacology<\/a> in March 2026. Part 3 (8 mg + 12 mg, monotherapy, n = 12) <a href=\"https:\/\/ir.ataibeckley.com\/news-releases\/news-release-details\/atai-life-sciences-and-beckley-psytech-report-positive-phase-2a\" rel=\"nofollow\" target=\"_blank\">topline announced<\/a> September 2025. Part 4 (8 mg + 8 mg, adjunctive) ongoing; initial data expected Q4 2026.<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Endpoint<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Safety and tolerability; exploratory Montgomery-Asberg Depression Rating Scale (MADRS) total score change from baseline<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Responder Rate (Day 2)<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">66.7% of participants achieved \u226550% MADRS reduction from a single dose<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Durability (Day 85)<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">83% responders (10 mg cohort); 66.7% (12 mg cohort)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>MADRS<\/strong><br \/>\n            <strong>\u2011<\/strong><br \/>\n            <strong>6 Core Symptoms<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">19.2 \u2192 6.2 (10 mg); 21.0 \u2192 9.3 (12 mg); \u226410 = remission<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Safety<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">No serious adverse events; majority of drug\u2011related AEs transient and resolved on same day<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Discharge Readiness<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Mean ~100 minutes post\u2011dose<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Phase 3 Status<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">End-of-Phase 2 meeting with U.S. FDA completed; Phase 3 initiation on track for Q2 2026<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong><br \/>\n          <br \/>Management Commentary<\/strong><br \/>\n        <br \/>Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley said: <em>&#8220;A 66.7% Day\u20112 response rate with a single intranasal dose of BPL\u2011003, maintained through Week 12 in the 10 mg cohort, represents a compelling clinical signal in patients who remained on their baseline SSRI therapy. Combined with our statistically significant double-blind, randomized Phase 2b results in 193 participants and our recent FDA End\u2011of\u2011Phase 2 alignment, these Phase 2a data reinforce the potential of BPL\u2011003 to transform the treatment paradigm for TRD as we prepare to initiate Phase 3 in Q2 2026.\u201d<\/em><\/p>\n<p>Dr. Kevin Craig, Chief Medical Officer at AtaiBeckley, added: <em>\u201cThis study provides the first Phase 2a evidence that BPL\u2011003 can be administered alongside SSRIs without compromising efficacy or safety, a meaningful advance given that many TRD patients remain on chronic SSRI therapy. The rapid resolution of acute effects and ~100\u2011minute discharge readiness further support the feasibility of integrating BPL\u2011003 into existing interventional psychiatry settings.\u201d<\/em><\/p>\n<p>\n        <strong>Study Details<\/strong><br \/>\n        <br \/>The 12-week, open-label, single-center, ascending-dose trial enrolled 12 adults aged 18 to 75 years with moderate-to-severe major depressive disorder (baseline MADRS \u226524) and TRD. All participants had failed at least two prior antidepressants and remained on a stable dose of one of four SSRIs &#8211; citalopram, escitalopram, sertraline or fluoxetine &#8211; throughout the study. Six participants received a single intranasal 10 mg dose of BPL-003 and six received a single intranasal 12 mg dose of BPL-003, with psychological support before, during and after dosing. Participants were followed for 12 weeks.<\/p>\n<p>This publication represents Part 2 of the four-part Phase 2a open-label study. Data from Part 1 (BPL-003 monotherapy, 10 mg single dose, n=12) was published in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cGSBeYOw3OobgqvBv7EaN4HcwMTDCPSSe9UMTtMtBuLOIdG0SGUYyBoU4mx2yFoUBZ9G3ezNn0btdTCb8PSVVHHfyFxEKOPsYv9mzagLzTfBw1XCqhI7EIQHflFiG3T0dwNcOPq7q-7MavwXukMyihsQ7gz2miXieXWiYh2ZKnqf4hycCg0gT_36CYjbGzbWMkjZHRWjkPGxRQIO0dxhvsT4EwltKdacvKnpJ_f2MDR3MHYOCZnOpy5FG236KM9c2A4OM4dwIY_AkUc6hQm0lA==\" rel=\"nofollow\" target=\"_blank\">Journal of Psychopharmacology in March 2026<\/a>, reporting a mean 12.6-point MADRS reduction by Day 2, sustained through 12 weeks. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=II1PCOX1Dd0jpdZqUnkWm-MLHN33VPDo0H0o4AuQbgCELkeglQkjVUz4cMrXzMzoqGs31BwO2Fd9Q2ncnbT9zAOVNVIG6CikJOxIbejLmy-NydMkgaU3aAPTb5LQ0OkFPHPh-jm3B8xWJeS3PzbVOqoOLL_Fk6P1YHUKoDPuVqsW8GhleluazqS_HxhmATI8Vwb8_KcMXPDNJIWYnOp9hQcpTrYjwArPIKhl1aeEBf8=\" rel=\"nofollow\" target=\"_blank\">Topline data<\/a> from Part 3 (8 mg + 12 mg, BPL-003 monotherapy, n=12) were announced in September 2025, showing that a second dose of BPL-003 at Week 2 has the potential to induce additional reductions in MADRS scores without impact on the safety and tolerability profile of the treatment. Part 4 of the program &#8211; evaluating a two-dose induction regimen of BPL-003 (8 mg + 8 mg) in participants with TRD who are also receiving defined antidepressants \u2013 is ongoing. Initial data from that cohort is expected in Q4 2026.<\/p>\n<p>\n        <strong>About BPL-003<\/strong><br \/>\n        <br \/>BPL-003 is a patent-protected, proprietary intranasal formulation of mebufotenin benzoate (5-MeO-DMT), administered via a nasal spray device used in a previously approved drug product. BPL-003 is designed to deliver rapid and durable effects from a single dose, with a short psychedelic duration, and is being investigated as a potential therapy for treatment-resistant depression (TRD) and alcohol use disorder (AUD). BPL-003 has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration and is covered by granted US, UK and European composition-of-matter patents, with multiple further claims pending in various jurisdictions.<\/p>\n<p>\n        <strong>About Treatment Resistant Depression<\/strong><br \/>\n        <br \/>Treatment-resistant depression affects an estimated 30% of the nearly 300 million people living with depression around the globe, representing one of the largest areas of unmet need in psychiatry. TRD occurs when a patient does not achieve an adequate response following at least two courses of antidepressants.<\/p>\n<p>\n        <strong>About AtaiBeckley Inc.<br \/><\/strong>AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley\u2019s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.<\/p>\n<p align=\"justify\">For the latest updates and to learn more about the AtaiBeckley mission, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1goMqH-aif4-XweB4Z3G5eTcGys8QO45cnW3JPFYUKOxo75a1-Ok0Ky0W7riniU49y0bRwxlmMa_GjUQ8D0nXeneYZyifk7vWT-lC3-Ai3k=\" rel=\"nofollow\" target=\"_blank\">www.ataibeckley.com<\/a> or follow the Company on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=115Kt2pi9gBOLoKjdFhDGVaTJFprWpq1FGPtxhLJ49lu26U3td1WjdlbcXYT0ykIS5gPSXhLSJ-zJjBXoqWrM4vfrve1qdlHpo9TROym-QSRIC1sjVGdkxaLbdc8Mx0a\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7foTXlfK8V3o8eRecuttSYy_5ZbshUPiNvhNkySU7K_Wneej06i4YIlTSNJRIjQwoFHl7BUGmaNBWOTmf6WeLA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cinitiate,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201cplan,\u201d \u201cpotentially,\u201d \u201cpreliminary,\u201d \u201clikely,\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: our business strategy and plans; expectations regarding the outcome of regulatory discussions regarding the development of BPL-003; expectations regarding the advancement into Phase 3 studies in adults with TRD and related milestones; expectations regarding the design of the Phase 3 program; and the potential benefits of BPL-003 for patients with TRD.<\/p>\n<p align=\"justify\">Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled \u201cRisk Factors\u201d in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (\u201cSEC\u201d), as such factors may be updated from time to time in our quarterly reports and other filings with the SEC. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.<\/p>\n<p>\n        <strong>Contact Information:<\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>Investors: <\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Jason Awe, PhD<br \/>VP, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8FGWTNmxXvo4rrMD2kP81AombxHnG5Y5l1xVU-7Wa2-ZfMTD87UaMgZJqtN0O8nMKeO9X1GKMMU9Q49afLXQhvuRpeB6OIHMhTe8yWLj5MM=\" rel=\"nofollow\" target=\"_blank\">IR@ataibeckley.com<\/a><\/p>\n<p>\n        <strong><br \/>\n          <em>Media: <\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Charlotte Chorley<br \/>Associate Director, Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=juVLWw7otCXM1-UG2eCcRavvzsuxa4u5UuewQlYNYGtwwpmCRZ7tIlTdcGd0jENoHlmwaDkrq77_-PdaE80u_QOg-3kOMrvXr6_As6q0ZOU=\" rel=\"nofollow\" target=\"_blank\">PR@ataibeckley.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjAwOCM3NTI0ODgzIzIyMDY1ODk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmQwMTlmOWQtYmFiYi00N2E1LWFjOTUtNDM1NDhlMWIxNDAzLTEyMTgxNDItMjAyNi0wNC0wOC1lbg==\/tiny\/AtaiBeckley-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts Durable responses observed at Day 85: 83% (5\/6) (10 mg) and 66.7% (4\/6) (12 mg) BPL-003 received FDA Breakthrough Therapy Designation in October 2025 Phase 3 initiation on track for Q2 2026 NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) &#8212; AtaiBeckley Inc. (NASDAQ: ATAI) (\u201cAtaiBeckley\u201d or \u201cCompany\u201d), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced peer-reviewed Phase 2a results (NCT05660642) in CNS Drugs demonstrating that a single intranasal dose of BPL-003 (mebufotenin benzoate), which holds FDA Breakthrough Therapy &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949716","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts Durable responses observed at Day 85: 83% (5\/6) (10 mg) and 66.7% (4\/6) (12 mg) BPL-003 received FDA Breakthrough Therapy Designation in October 2025 Phase 3 initiation on track for Q2 2026 NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) &#8212; AtaiBeckley Inc. (NASDAQ: ATAI) (\u201cAtaiBeckley\u201d or \u201cCompany\u201d), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced peer-reviewed Phase 2a results (NCT05660642) in CNS Drugs demonstrating that a single intranasal dose of BPL-003 (mebufotenin benzoate), which holds FDA Breakthrough Therapy &hellip; Continue reading &quot;AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T10:03:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjAwOCM3NTI0ODgzIzIyMDY1ODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs\",\"datePublished\":\"2026-04-08T10:03:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\\\/\"},\"wordCount\":1306,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjAwOCM3NTI0ODgzIzIyMDY1ODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\\\/\",\"name\":\"AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjAwOCM3NTI0ODgzIzIyMDY1ODk=\",\"datePublished\":\"2026-04-08T10:03:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjAwOCM3NTI0ODgzIzIyMDY1ODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjAwOCM3NTI0ODgzIzIyMDY1ODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/","og_locale":"en_US","og_type":"article","og_title":"AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - Market Newsdesk","og_description":"66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts Durable responses observed at Day 85: 83% (5\/6) (10 mg) and 66.7% (4\/6) (12 mg) BPL-003 received FDA Breakthrough Therapy Designation in October 2025 Phase 3 initiation on track for Q2 2026 NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) &#8212; AtaiBeckley Inc. (NASDAQ: ATAI) (\u201cAtaiBeckley\u201d or \u201cCompany\u201d), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced peer-reviewed Phase 2a results (NCT05660642) in CNS Drugs demonstrating that a single intranasal dose of BPL-003 (mebufotenin benzoate), which holds FDA Breakthrough Therapy &hellip; Continue reading \"AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-08T10:03:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjAwOCM3NTI0ODgzIzIyMDY1ODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs","datePublished":"2026-04-08T10:03:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/"},"wordCount":1306,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjAwOCM3NTI0ODgzIzIyMDY1ODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/","name":"AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjAwOCM3NTI0ODgzIzIyMDY1ODk=","datePublished":"2026-04-08T10:03:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjAwOCM3NTI0ODgzIzIyMDY1ODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjAwOCM3NTI0ODgzIzIyMDY1ODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-resistant-depression-patients-on-ssris-phase-2a-data-published-in-cns-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AtaiBeckley\u2019s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949716"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949716\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}